Skip to content

Renal Sympathetic Denervation Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study

Renal Sympathetic Denervation Restores Autonomic Imbalance and Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01990911
Acronym
RDPAF
Enrollment
80
Registered
2013-11-25
Start date
2013-03-31
Completion date
2022-06-06
Last updated
2022-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Autonomic Imbalance, Hypertension, Hypertensive Heart Disease

Keywords

hypertension, hypertensive heart disease, atrial fibrillation, autonomic imbalance

Brief summary

The autonomic nervous system plays an important role in the precipitation of AF in structurally-abnormal hearts. Restoration of autonomic imbalance may therefore prevent new-onset AF. Renal artery denervation (RDN) is a novel percutaneous procedure that uses radio-frequency energy to destroy the sympathetic renal nerves. Symplicity 1 and -2 studies have shown that RDN effectively reduces blood pressure in up to 80% of treated patients. LVH regression and improvement of diastolic dysfunction follow as a consequence of afterload reduction and renin-angiotensin-aldosterone system modulation. RDN may thus also reduce intra-atrial pressure resulting in less stretch of the pulmonary venous ostia where most ectopic AF-foci originate. Hypothesis: RDN restores autonomic imbalance in HTHD and lowers intra-atrial pressure by reducing afterload. These synergistic mechanisms may prevent new-onset AF.

Detailed description

One hundred consenting patients meeting all inclusion criteria will undergo an exercise stress test, 2D and M-Mode echocardiograms and 24-hour ambulatory blood pressure holter monitoring prior to being randomised to receive either renal denervation (RDN) with a Symplicity renal denervation catheter plus medical therapy or medical therapy alone. Coronary angiography with/without coronary revascularisation will be performed as per the treating cardiologist's clinical judgement and a Reveal® holter will be implanted in all patients at the end of the procedure. Time zero will be defined as starting at three months after the procedure. Follow up visits will be scheduled to scan the holter for the primary end point, i.e. high atrial rates (AF-surrogate defined as: episodes of atrial rate \>190 beats per minute for more than 6 minutes) or new-onset AF. Patients will be followed six monthly for three years.

Interventions

DEVICERenal denervation

In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.

DRUGMedical therapy

Subjects will continue on their standard medical therapy as prescribed by their treating physician

Sponsors

University Hospital, Saarland
CollaboratorOTHER
Pace Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must have an indication for coronary angiography e.g. * Acute coronary syndrome * Positive stress ECG: - Defined as ≥1mm ST segment shift (depression or elevation) in ≥2 contiguous leads with/without chest discomfort) * Age ≥55 years * Office blood pressure ≥160/90mmHg in non-diabetics or ≥150/90mmHg in diabetics * Subjects must be on at least 3 anti-hypertensive drugs, including a diuretic agent * Sinus rhythm * Left ventricular hypertrophy defined on echo as: * Estimated LV mass \> 255 g or LVMI \>131 g/m2 for men * Estimated LV mass \>193 g or LVMI \>113 g/m2for women * Left atrial diameter ≥45mm on any echocardiographic window

Exclusion criteria

* Estimated glomerular filtration rate (eGFR) \< 45ml/min/1.73m2 * Renal artery anatomy unsuitable for RDN * Substantial stenotic valvular heart disease * Pregnancy or planned pregnancy * Thyrotoxicosis * Patients needing to undergo coronary artery bypass surgery

Design outcomes

Primary

MeasureTime frameDescription
Atrial fibrillation3 yearsSubclinical atrial tachyarrhythmias (episodes of atrial rate \>190 beats per minute for more than 6 minutes) or atrial fibrillation recorded by implantable loop recorder (Reveal® holter).

Secondary

MeasureTime frameDescription
Restoration of autonomic imbalance3 yearsRestoration of autonomic imbalance: lowering resting heart rate, prolonging the PR-interval and improving heart rate recovery after exercise.

Countries

South Africa

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026